Q4 2017 13F Holders as of 12/31/2017
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
34.2M
-
Shares change
-
+1.1M
-
Total reported value, excl. options
-
$173M
-
Value change
-
+$4.99M
-
Put/Call ratio
-
0.06
-
Number of buys
-
28
-
Number of sells
-
-24
-
Price
-
$5.05
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2017
65 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q4 2017.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.2M shares
of 193M outstanding shares and own 17.69% of the company stock.
Largest 10 shareholders include QVT Financial LP (16M shares), RTW INVESTMENTS, LP (5.15M shares), PRIMECAP MANAGEMENT CO/CA/ (4M shares), LADENBURG THALMANN FINANCIAL SERVICES INC. (1.77M shares), D. E. Shaw & Co., Inc. (1.21M shares), BANK OF MONTREAL /CAN/ (863K shares), BlackRock Inc. (751K shares), MORGAN STANLEY (629K shares), AXA (541K shares), and RENAISSANCE TECHNOLOGIES LLC (403K shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.